title: Gene expression profiles in human and mouse primary cells provide new insights into the differential actions of vitamin D3 metabolites.
abstract: 1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) had earlier been regarded as the only active hormone. The newly identified actions of 25-hydroxyvitamin D3 (25(OH)D3) and 24R,25-dihydroxyvitamin D3 (24R,25(OH)2D3) broadened the vitamin D3 endocrine system, however, the current data are fragmented and a systematic understanding is lacking. Here we performed the first systematic study of global gene expression to clarify their similarities and differences. Three metabolites at physiologically comparable levels were utilized to treat human and mouse fibroblasts prior to DNA microarray analyses. Human primary prostate stromal P29SN cells (hP29SN), which convert 25(OH)D3 into 1α,25(OH)2D3 by 1α-hydroxylase (encoded by the gene CYP27B1), displayed regulation of 164, 171, and 175 genes by treatment with 1α,25(OH)2D3, 25(OH)D3, and 24R,25(OH)2D3, respectively. Mouse primary Cyp27b1 knockout fibroblasts (mCyp27b1 (-/-)), which lack 1α-hydroxylation, displayed regulation of 619, 469, and 66 genes using the same respective treatments. The number of shared genes regulated by two metabolites is much lower in hP29SN than in mCyp27b1 (-/-). By using DAVID Functional Annotation Bioinformatics Microarray Analysis tools and Ingenuity Pathways Analysis, we identified the agonistic regulation of calcium homeostasis and bone remodeling between 1α,25(OH)2D3 and 25(OH)D3 and unique non-classical actions of each metabolite in physiological and pathological processes, including cell cycle, keratinocyte differentiation, amyotrophic lateral sclerosis signaling, gene transcription, immunomodulation, epigenetics, cell differentiation, and membrane protein expression. In conclusion, there are three distinct vitamin D3 hormones with clearly different biological activities. This study presents a new conceptual insight into the vitamin D3 endocrine system, which may guide the strategic use of vitamin D3 in disease prevention and treatment.
authors.affiliation: Department of Anatomy, Medical School, University of Tampere, Tampere, Finland ; Department of Clinical Chemistry, Tampere University Hospital, University of Tampere, Tampere, Finland.
authors.forename: Pentti
authors.initials: P
authors.lastname: Tuohimaa
authors.forename: Jing-Huan
authors.initials: JH
authors.lastname: Wang
authors.forename: Sofia
authors.initials: S
authors.lastname: Khan
authors.forename: Marianne
authors.initials: M
authors.lastname: Kuuslahti
authors.forename: Kui
authors.initials: K
authors.lastname: Qian
authors.forename: Tommi
authors.initials: T
authors.lastname: Manninen
authors.forename: Petri
authors.initials: P
authors.lastname: Auvinen
authors.forename: Mauno
authors.initials: M
authors.lastname: Vihinen
authors.forename: Yan-Ru
authors.initials: YR
authors.lastname: Lou
mesh_terms: D000818:Animals; D002112:Calcifediol / Q000494:pharmacology*; D002117:Calcitriol / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002762:Cholecalciferol / Q000378:metabolism* / Q000494:pharmacology; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D020869:Gene Expression Profiling; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D017154:Stromal Cells / Q000187:drug effects* / Q000378:metabolism
chemical_list: D002762:Cholecalciferol; D002117:Calcitriol; D002112:Calcifediol